Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...

Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

The company highlighted that about 90% of proteins associated with diseases cannot be targeted with traditional therapies due ...

US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Takeda Pharmaceutical Stock Up 1.6 % Shares of Takeda Pharmaceutical stock opened at $14.08 on Friday. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08 ...

In this article, we are going to take a look at where Takeda Pharmaceutical Company Limited (NYSE:TAK) stands against the other pharma stocks. Healthcare, which includes numerous businesses that ...